Article

Circadian regulation of <i>MGMT</i> expression and promoter methylation underlies daily rhythms in TMZ sensitivity in glioblastoma

2023-09-17

Abstract excerpt

<h4>Background</h4> Glioblastoma (GBM) is the most common primary brain tumor in adults. Despite extensive research and clinical trials, median survival post-treatment remains at 15 months. Thus, all opportunities to optimize current treatments and improve patient outcomes should be considered. A recent retrospective clinical study found that taking TMZ in the morning compared to the evening was associated with a...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: d2aa504c-7014-50b7-98f0-b8ee76c47cfd
DOI: 10.1101/2023.09.13.557630

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Circadian regulation of <i>MGMT</i> expression and promoter methylation underlies daily rhythms in TMZ sensitivity in glioblastomaDOI 10.1101/2023.09.13.557630Read

Daily glucocorticoids promote glioblastoma growth and circadian synchrony to the hostSemantic proximity Read

Advancing Clinical Response Against Glioblastoma: Evaluating SHP1705 CRY2 Activator Efficacy in Preclinical Models and Safety in Phase I TrialsSemantic proximity Read

Advancing clinical response against glioblastoma: Evaluating SHP1705 CRY2 activator efficacy in preclinical models and safety in phase I trialsSemantic proximity Read

Differential expression of the circadian clock network correlates with tumour progression in gliomas.Semantic proximity Read

IDH1 gene mutation activates Smad signaling molecules to regulate the expression levels of cell cycle and biological rhythm genes in human glioma U87‑MG cells.Semantic proximity Read

Efficacy of protracted temozolomide dosing is limited in MGMT unmethylated GBM xenograft modelsSemantic proximity Read

MGMT inhibition regulates radioresponse in GBM, GSC, and melanomaSemantic proximity Read

Assessing <i>MGMT</i> methylation status and its current impact on treatment in glioblastomaSemantic proximity Read

Repurposing chlorpromazine as add-on in the adjuvant phase of first-line glioblastoma therapeutic protocol in patients carrying hypo-/un-methylated<i>MGMT</i>gene promoter: RACTAC, a Phase II multicenter single-arm clinical trialSemantic proximity Read

Timing Matters: Overall Treatment Time, Radiotherapy Interruptions, and Outcomes in glioblastomas – Prognostic Significance in Different Biological Sub- GroupsSemantic proximity Read

Circadian genesPer1andPer2increase radiosensitivity of gliomain vivoSemantic proximity Read

Circadian Regulator CLOCK Recruits Immune-Suppressive Microglia into the GBM Tumor MicroenvironmentSemantic proximity Read